NCT02299349View on ClinicalTrials.gov

Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions
Total Knee Arthroplasty
Interventions
DRUG

bupivacaine liposome suspension

bupivacaine liposome suspension periarticular injection

DRUG

concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL

Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl

All Listed Sponsors
lead

TriHealth Inc.

OTHER

NCT02299349 - Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection | Biotech Hunter | Biotech Hunter